Salvianolic acid B attenuates liver fibrosis by targeting Ecm1 and inhibiting hepatocyte ferroptosis

Salvianolic acid B attenuates liver fibrosis by targeting Ecm1 and inhibiting hepatocyte ferroptosis

2024 | Yadong Fu, Xiaoxi Zhou, Lin Wang, Weiguo Fan, Siqi Gao, Danyan Zhang, Zhiyang Ling, Yaguang Zhang, Liyan Ma, Fang Bai, Jiamei Chen, Bing Sun, Ping Liu
This study investigates the mechanism by which Salvianolic acid B (Sal B) attenuates liver fibrosis by targeting extracellular matrix protein 1 (Ecm1) and inhibiting hepatocyte ferroptosis. Sal B, a natural antioxidant, has been shown to have antifibrotic effects, but its specific mechanism remains unclear. The researchers induced liver fibrosis in wild-type and Ecm1-deficient mice using carbon tetrachloride (CCl4) and treated them with Sal B, ferrostatin-1, sorafenib, or cilengitide. They found that Sal B significantly reduced liver fibrosis in CCl4-induced mice, and this effect was abolished in Ecm1-deficient hepatocytes. Mechanistically, Sal B protected hepatocytes from ferroptosis by upregulating Ecm1. Further studies revealed that Ecm1 interacts with xCT to regulate hepatocyte ferroptosis. In vitro, Sal B treatment reduced hepatocyte ferroptosis, which was abrogated by Ecm1 knockdown in LO2 cells. These findings suggest that Sal B alleviates liver fibrosis by upregulating Ecm1 and inhibiting hepatocyte ferroptosis, with Ecm1 interacting with xCT to regulate this process.This study investigates the mechanism by which Salvianolic acid B (Sal B) attenuates liver fibrosis by targeting extracellular matrix protein 1 (Ecm1) and inhibiting hepatocyte ferroptosis. Sal B, a natural antioxidant, has been shown to have antifibrotic effects, but its specific mechanism remains unclear. The researchers induced liver fibrosis in wild-type and Ecm1-deficient mice using carbon tetrachloride (CCl4) and treated them with Sal B, ferrostatin-1, sorafenib, or cilengitide. They found that Sal B significantly reduced liver fibrosis in CCl4-induced mice, and this effect was abolished in Ecm1-deficient hepatocytes. Mechanistically, Sal B protected hepatocytes from ferroptosis by upregulating Ecm1. Further studies revealed that Ecm1 interacts with xCT to regulate hepatocyte ferroptosis. In vitro, Sal B treatment reduced hepatocyte ferroptosis, which was abrogated by Ecm1 knockdown in LO2 cells. These findings suggest that Sal B alleviates liver fibrosis by upregulating Ecm1 and inhibiting hepatocyte ferroptosis, with Ecm1 interacting with xCT to regulate this process.
Reach us at info@study.space